Abstracts tagged "statin-induced myopathies and treatment"

Abstract Number: 388 • 2019 ACR/ARP Annual Meeting
Treating Statin-induced Anti-HMGCR Myopathy with Normal Muscle Strength: A New Window of Opportunity
Alain Meyer¹, Yves Troyanov ², Julie Drouin ³, Josiane Bourre-Tessier ⁴, Genevieve Oligny-Longpre ⁵, Océane Landon-Cardinal ⁶, Baptiste Hervier ⁷, Sabrina Hoa ⁸, Anne-Marie Mansour ⁹, Eric Rich ⁴, Jean-Richard Goulet ⁴, Sandra Chartrand ¹⁰, Marie Hudson ¹¹, Jessica Nehme ⁹, Jean-Paul Makhzoum ¹², Farah Zarka ⁹, Sara Hussein ¹³, Vincent Morin ¹⁴, Edith Villeneuve ¹⁵, Jean-Pierre Raynauld ¹⁶, Marianne Landry ¹⁷, Erin O'Ferrall ¹⁸, Jose Ferreira ¹⁹, Benjamin Ellezam ²⁰, Jason Karamchandani ¹⁸, Sandrine Larue ²¹, Rami Massie ¹⁸, Catherine Isabelle ²¹, isabelle Deschênes ⁵, Valérie Leclair ²², Helene Couture ²³, Ira Targoff ²⁴, Marvin Fritzler ²⁵ and Jean-Luc Senecal ⁴, ¹Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Centre hospitalier regional de Trois-Rivieres, Trois-Rivieres, QC, Canada, ⁴Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ⁵Hôpital du Haut-Richelieu, Saint-Jean-sur-Richelieu, QC, Canada, ⁶Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montreal, QC, Canada, ⁷Hopital Pitie-Salpetriere, Paris, France, ⁸University of Montreal, Montreal, QC, Canada, ⁹Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹⁰Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada, ¹¹Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ¹²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹³Centre hospitalier regional de Lanaudiere, Saint-Charles-Borromée, QC, Canada, ¹⁴Universite Laval, Quebec, QC, Canada, ¹⁵Institut de Recherche en Rhumatologie de Montréal, Montreal, QC, Canada, ¹⁶Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹⁷Hôpital LaSalle, Montreal, QC, Canada, ¹⁸Montreal Neurological Institute, Montreal, QC, Canada, ¹⁹Hopital Maisonneuve-Rosemont, Montreal, QC, Canada, ²⁰Centre hospitalier universitaire Sainte-Justine, Montreal, QC, Canada, ²¹Hôpital Charles-Le Moyne, Greenfield Park, QC, Canada, ²²Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ²³Hôpital Enfant-Jesus, Quebec, QC, Canada, ²⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Anti-HMGCR myopathy has recently been defined as a subset of immune-mediated necrotizing myopathies characterized by proximal muscle weakness, elevated CK levels and the presence…
Abstract Number: 948 • 2015 ACR/ARHP Annual Meeting
Autoimmune Myopathies: Effects of Intravenous Immunoglobulin Therapy on Muscle Strength and Predictors of Response
Arash Lahoutiharahdashti¹, Iago Pinal-Fernandez², Jemima Albayda¹, Julie J. Paik³, Sonye K. Danoff⁴, Andrew Mammen⁵ and Lisa Christopher-Stine⁶, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Autoimmune Systemic Diseases Unit, Vall D’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, ⁵Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Ste 4100 Rm 409, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: There is a variable response rate to Intravenous immunoglobulin (IVIG) in patients with autoimmune myopathies. The aim of this study was to determine whether…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].